- Home
- ANAB vs AMSF Comparison
ANAB vs AMSF Comparison
Compare ANAB & AMSF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANAB
- AMSF
- Stock Information
- Founded
- ANAB 2005
- AMSF 1985
- Country
- ANAB United States
- AMSF United States
- Employees
- ANAB N/A
- AMSF N/A
- Industry
- ANAB Biotechnology: Pharmaceutical Preparations
- AMSF Accident &Health Insurance
- Sector
- ANAB Health Care
- AMSF Finance
- Exchange
- ANAB Nasdaq
- AMSF Nasdaq
- Market Cap
- ANAB 759.5M
- AMSF 918.6M
- IPO Year
- ANAB 2017
- AMSF 2005
- Fundamental
- Price
- ANAB $22.23
- AMSF $47.47
- Analyst Decision
- ANAB Buy
- AMSF Buy
- Analyst Count
- ANAB 10
- AMSF 2
- Target Price
- ANAB $42.25
- AMSF $59.50
- AVG Volume (30 Days)
- ANAB 559.5K
- AMSF 81.7K
- Earning Date
- ANAB 05-05-2025
- AMSF 07-28-2025
- Dividend Yield
- ANAB N/A
- AMSF 9.52%
- EPS Growth
- ANAB N/A
- AMSF N/A
- EPS
- ANAB N/A
- AMSF 2.48
- Revenue
- ANAB $111,872,000.00
- AMSF $301,216,000.00
- Revenue This Year
- ANAB N/A
- AMSF $1.69
- Revenue Next Year
- ANAB $9.72
- AMSF $6.54
- P/E Ratio
- ANAB N/A
- AMSF $19.15
- Revenue Growth
- ANAB 387.20
- AMSF N/A
- 52 Week Low
- ANAB $12.21
- AMSF $41.97
- 52 Week High
- ANAB $41.31
- AMSF $60.24
- Technical
- Relative Strength Index (RSI)
- ANAB 62.32
- AMSF 49.34
- Support Level
- ANAB $20.50
- AMSF $45.80
- Resistance Level
- ANAB $22.84
- AMSF $48.54
- Average True Range (ATR)
- ANAB 1.28
- AMSF 1.01
- MACD
- ANAB 0.12
- AMSF 0.13
- Stochastic Oscillator
- ANAB 83.24
- AMSF 60.95
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About AMSF AMERISAFE Inc.
AMERISAFE Inc is a specialty provider of workers' compensation insurance focused on small to mid-sized employers engaged in hazardous industries, principally construction, trucking, logging and lumber, agriculture, manufacturing, maritime, and telecommunications. The company generates a majority of its revenue in the form of premiums.